IL278304A - - Google Patents
Info
- Publication number
- IL278304A IL278304A IL27830420A IL27830420A IL278304A IL 278304 A IL278304 A IL 278304A IL 27830420 A IL27830420 A IL 27830420A IL 27830420 A IL27830420 A IL 27830420A IL 278304 A IL278304 A IL 278304A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278304A true IL278304A (enExample) | 2020-12-31 |
| IL278304B1 IL278304B1 (en) | 2024-02-01 |
| IL278304B2 IL278304B2 (en) | 2024-06-01 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309955A IL309955A (en) | 2018-04-27 | 2019-04-26 | Integrin-targeting ligands and their uses |
| IL278304A IL278304B2 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309955A IL309955A (en) | 2018-04-27 | 2019-04-26 | Integrin-targeting ligands and their uses |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12667619B2 (enExample) |
| EP (2) | EP4435000A3 (enExample) |
| JP (2) | JP7704529B2 (enExample) |
| KR (1) | KR102787533B1 (enExample) |
| CN (2) | CN112074290B (enExample) |
| AU (1) | AU2019260738B2 (enExample) |
| BR (1) | BR112020021949A2 (enExample) |
| CA (1) | CA3097656A1 (enExample) |
| DK (1) | DK3784269T3 (enExample) |
| ES (1) | ES2983950T3 (enExample) |
| FI (1) | FI3784269T3 (enExample) |
| HR (1) | HRP20240907T1 (enExample) |
| IL (2) | IL309955A (enExample) |
| JO (1) | JOP20200266A1 (enExample) |
| MX (1) | MX2020011290A (enExample) |
| SA (1) | SA520420426B1 (enExample) |
| SG (1) | SG11202009734VA (enExample) |
| SI (1) | SI3784269T1 (enExample) |
| TW (1) | TW202014206A (enExample) |
| WO (1) | WO2019210200A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309955A (en) | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
| KR20210113273A (ko) | 2019-01-09 | 2021-09-15 | 애로우헤드 파마슈티컬스 인코포레이티드 | HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| EP4367246A4 (en) * | 2021-07-07 | 2026-07-29 | Alnylam Pharmaceuticals Inc | Integrin-targeting ligands for the ocular administration of arni compounds |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| SK9192000A3 (en) * | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| AU2002337954C1 (en) | 2001-10-22 | 2008-10-23 | The Scripps Research Institute | Integrin targeting compounds |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP3673922A1 (en) * | 2008-03-14 | 2020-07-01 | VisEn Medical, Inc. | Integrin targeting agents and methods of using same |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| US9586916B2 (en) * | 2012-01-27 | 2017-03-07 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 |
| JP6383735B2 (ja) | 2013-01-28 | 2018-08-29 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｒｓウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン |
| HK1214301A1 (zh) * | 2013-02-28 | 2016-07-22 | 箭头研究公司 | 治療epas1相關疾病的有機組合物 |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| EP3273965A4 (en) | 2015-03-26 | 2018-12-05 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| TWI761305B (zh) | 2015-05-29 | 2022-04-21 | 美商愛羅海德製藥公司 | 抑制Ｈｉｆ２α基因表現之組合物及方法 |
| CN120247964A (zh) | 2018-02-17 | 2025-07-04 | 箭头药业股份有限公司 | 三炔连接剂和使用方法 |
| IL309955A (en) * | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
-
2019
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 US US17/050,042 patent/US12667619B2/en active Active
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt not_active Application Discontinuation
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202014206A (zh) | 2020-04-16 |
| AU2019260738B2 (en) | 2025-01-30 |
| FI3784269T3 (fi) | 2024-07-03 |
| CN118994152A (zh) | 2024-11-22 |
| JOP20200266A1 (ar) | 2020-10-21 |
| EP4435000A3 (en) | 2025-02-19 |
| HRP20240907T1 (hr) | 2024-10-25 |
| JP7704529B2 (ja) | 2025-07-08 |
| KR20210005145A (ko) | 2021-01-13 |
| IL309955A (en) | 2024-03-01 |
| US12667619B2 (en) | 2026-06-30 |
| MX2020011290A (es) | 2020-11-13 |
| IL278304B1 (en) | 2024-02-01 |
| ES2983950T3 (es) | 2024-10-28 |
| SA520420426B1 (ar) | 2024-11-19 |
| IL278304B2 (en) | 2024-06-01 |
| JP2025060958A (ja) | 2025-04-10 |
| CN112074290A (zh) | 2020-12-11 |
| CA3097656A1 (en) | 2019-10-31 |
| SI3784269T1 (sl) | 2024-08-30 |
| KR102787533B1 (ko) | 2025-03-31 |
| DK3784269T3 (da) | 2024-07-08 |
| WO2019210200A1 (en) | 2019-10-31 |
| AU2019260738A1 (en) | 2020-10-15 |
| EP3784269A1 (en) | 2021-03-03 |
| US20210093725A1 (en) | 2021-04-01 |
| BR112020021949A2 (pt) | 2021-01-26 |
| CN112074290B (zh) | 2024-09-10 |
| JP2021522269A (ja) | 2021-08-30 |
| EP4435000A2 (en) | 2024-09-25 |
| EP3784269A4 (en) | 2022-03-23 |
| EP3784269B1 (en) | 2024-06-05 |
| SG11202009734VA (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021000792B8 (enExample) | ||
| AT524834A2 (enExample) | ||
| AT521543A3 (enExample) | ||
| AT524266A2 (enExample) | ||
| BR102019026286B1 (pt) | Método e aparelho para o avanço de produtos a serem moldados | |
| BR102019025884B1 (pt) | Sistema de segurança aprimorado para máquinas de operação de autopropulsão | |
| BR102019023514B1 (pt) | Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna | |
| BR112020016338B1 (pt) | Dispositivo para tratamento de tecido corporal | |
| BR112021004021B1 (pt) | Método e sistema para produzir um resíduo de rejeitos empilhável | |
| BR112020023795B1 (pt) | Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção | |
| BR112021000922B1 (pt) | Tela de filtro, e, método para purificar água de alimentação | |
| BR112020026077B1 (pt) | Recipiente com estrutura encaixável | |
| BR112020026721B1 (pt) | Aparelho de moldagem para modar uma folha de um material contendo alcaloides | |
| BR102019012845B1 (pt) | Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga | |
| BR112020023832B1 (pt) | Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral | |
| BR112020024987B1 (pt) | Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico | |
| BR112020023823B1 (pt) | Distribuidor | |
| BR112020022482B1 (pt) | Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico | |
| BR112020022658B1 (pt) | Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido | |
| BR112020022516B1 (pt) | Processo para degomagem enzimática de óleo | |
| BR112020021042B1 (pt) | Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas | |
| BR112020020812B1 (pt) | Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado | |
| BR112020020476B1 (pt) | Filtro prensa e processo para operação de filtro prensa | |
| BR112020015757B1 (pt) | Métodos, sistema, kit e dispositivos para visualização e remoção de tumor | |
| BR102019000241B1 (pt) | Veículo modular, configurável, sobre plataforma de chassis comum, e métodos e sistemas associados |